Vivos Therapeutics Inc (VVOS)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $3.29M
Last updated: Nov 17, 2026 at 11:05 AM ET
Vivos Therapeutics Inc (VVOS) Stock Forecast
Analysts expect Vivos Therapeutics (VVOS) to earn -$1.40 per share in the fiscal year ending Dec 31, 2026, on revenue of $21.79M. Of 3 analysts, 2 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.33, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 2 | 66.7% |
| Hold | 1 | 33.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 56.4%.
- Fiscal year ending Dec 31, 2026
- -$1.40
- EPS consensus, revenue $21.79M
- Fiscal year ending Dec 31, 2027
- -$0.82
- EPS consensus, revenue $34.09M
- Next report
- Nov 17, 2026
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.40 | -$2.14 to -$0.75 | 3 | $21.79M | $21.79M to $21.79M | 1 |
| Dec 31, 2027 | -$0.82 | -$2.17 to -$0.10 | 3 | $34.09M | $24.50M to $45.08M | 3 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.27 | -$0.51 to -$0.07 | 6 | $6.76M | $5.88M to $8.24M | 6 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.39.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.40 | -$1.34 | -$1.34 | -$1.34 | -$1.39 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.82 | -$0.79 | -$0.79 | -$0.84 | -$0.35 | N/A |
Frequently Asked Questions About VVOS
What is the VVOS stock forecast?
Consensus analyst estimates put Vivos Therapeutics's EPS at -$1.40 for the fiscal year ending Dec 31, 2026, on revenue of $21.79M. The consensus rating from 3 analysts is Buy.
How do analysts rate VVOS stock?
Of 3 analysts covering Vivos Therapeutics, 0 rate it Strong Buy, 2 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from VVOS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.40, with estimates from -$2.14 to -$0.75 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.82, with estimates from -$2.17 to -$0.10 from 3 analysts.
What revenue do analysts expect from Vivos Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $21.79M, with estimates from $21.79M to $21.79M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $34.09M, with estimates from $24.50M to $45.08M.
How many analysts cover VVOS?
3 analysts rate Vivos Therapeutics stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
VVOS pages: Overview, Earnings, Forecast, Financials, Competitors